Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
Sagimet Biosciences priced a $115.0 million underwritten offering of 8,750,010 Series A common shares at $10.00, plus pre-funded warrants on 2,750,010 shares at $9.9999. The raise is led by Commodore Capital with participation from RA Capital, BVF Partners, and other institutional investors, and is expected to close on or about October 1, 2026.
Key figures
- Deal Value Usd
- 115000000
- Offering Price
- 10
- Shares Offered
- 8750010
- Use of proceeds
- Phase 3 denifanstat acne trial, pre-launch activities, TVB-3567 Phase 2 topline, topical FASN inhibitor IND, general corporate purposes
- Pre funded warrant price
- 9.9999
- Pre funded warrant shares
- 2750010
- Pre funded warrant exercise price
- 0.0001
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.